🇺🇸 FDA

Intelligence Platform

Patents

Browse 405 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 8580844

Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic mod

Georgia Regents Research Institute, Inc. · Granted Tue Nov 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8546433

Axl inhibitors for use in combination therapy for preventing, treating or managing metasta

Rigel Pharmaceuticals, Inc. · Granted Tue Oct 01 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8524500

Methods and compositions for targeted cleavage and recombination

Sangamo Biosciences, Inc. · Granted Tue Sep 03 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8501713

Drug combinations for the treatment of duchenne muscular dystrophy

Summit Corporation Plc · Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8501766

Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8486923

Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhi

TAKEDA GMBH · Granted Tue Jul 16 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 11 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8481529

Combination cancer chemotherapy

Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Jul 09 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8435497

Formoterol of and ciclesonide combination

TAKEDA GMBH · Granted Tue May 07 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8415384

Reducing myocardial reperfusion injury by the combination therapy of protein kinase A acti

The Board of Regents of the University of Texas System · Granted Tue Apr 09 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8394377

Methods for treating cancer using combination therapy

The Regents of the University of Colorado · Granted Tue Mar 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8388963

Antitumor combinations containing a VEGF-inhibiting agent and 5FU or a derivative thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8349810

Methods for targeted cleavage and recombination of CCR5

Sangamo Biosciences, Inc. · Granted Tue Jan 08 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 03 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8329753

Combination of compounds, or a bifunctional compound, that provides fatty acid metabolism

The Regents of the University of Colorado · Granted Tue Dec 11 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8268792

Use of an active ingredient combination that contains hydroxystilbene for preventing and/o

Reinhard Rettenberger · Granted Tue Sep 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8258116

Combination therapy for the treatment of HCV infection

Vertex Pharmaceuticals Incorporated · Granted Tue Sep 04 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 30 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8163542

Potent combinations of mRNA transport elements

The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Apr 24 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8158146

Stable combinations of amlodipine besylate and benazepril hydrochloride

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 17 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 12 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8119649

Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia

The Board of Regents of the University of Texas System · Granted Tue Feb 21 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 16 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8048418

Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and V

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 01 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 27 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7977320

Method of increasing efficacy of tumor cell killing using combinations of anti-neoplastic

The Regents of the University of California · Granted Tue Jul 12 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 07 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7972854

Methods and compositions for targeted cleavage and recombination

Sangamo Biosciences, Inc. · Granted Tue Jul 05 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 30 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7968511

Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jun 28 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 23 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7919484

Combination therapy

Xenon Pharmaceuticals Inc. · Granted Tue Apr 05 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 31 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7902148

Use of an echinocandin antifungal agent in combination with a glycopeptide antibacterial a

Theravance, Inc. · Granted Tue Mar 08 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 03 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted